Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 P167 | DOI: 10.1530/endoabs.90.P167

ECE2023 Poster Presentations Pituitary and Neuroendocrinology (123 abstracts)

Somatostatin analogue treatment is associated with lack of progression of pNETs <20mm in size in patients with MEN1

Isolda Frizelle , Anand Velusamy , Barbara McGowan , Louise Breen , Emma Duncan , Louise Izatt , Dimitra Christodoulou , Mamta Joshi & Carroll Paul


Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom


Introduction: Pancreatic neuroendocrine tumours (pNETs) are the main cause of mortality in patients with multiple endocrine neoplasia type 1 (MEN1). The CLARINET study demonstrated that somatostatin analogue treatment improved progression free survival in patients with enteropancreatic NETs but little is known about the role of SSA in preventing progression of pNETs in MEN1 (1). Many centres have started using SSA treatment in MEN1 patients with enlarging pNETs or tumours >15 mm. This is current practice in our centre.

Objective: This observational study examined the effectiveness of somatostatin analogue (SSA) treatment in preventing progression of pNETS in MEN1.

Methods: Using our database of MEN1 patients, electronic patient records were individually reviewed to document the radiological, biochemical and clinical behaviour of pNETs over time. Patients were treated with SSA if tumours had documented growth, were > 15 mm in size or were associated with metastases. We compared pNET size/ growth in patients treated and untreated with SSA (overwhelmingly lanreotide autogel 120 mg 4 weekly).

Results:

Demographics
Total MEN1 cohort
n57
Gender37F: 20M
Age (y)45 (16)
PNETs documented44 (12 surgical)
Deceased (n)8
Mean age of death, y (range)59 (41-84)
SSA use (%)35.1
Metastases N (%)4 (7.02)
Surgical intervention? N (%)16 (28.1)
Other Rx (n)Peptide receptor radiotherapy (PRRT) (n=2)
Included patients treated with SSA compared with untreated patients
MEN1 cohort with pNETs on SSAMEN1 cohort with pNETs not on SSA
n2012
Gender12F: 8M8F:4M
Age (y)42.2 (12.9)41.6 (17.6)
Deceased (n)32
Mean age of death (y)5651
Cause of deathsMetastatic pNET x2, metastatic gastrinomaACC, metastatic pNET
Surgical intervention? (n)31
PNET size (mm)(SD)15 (8)8 (4)
Stable disease118
Progression11
Improvement40
Data unavailable43
Duration of SSA use4- 120 (mean: 48)(SD 24)N/A
Duration of total surveillance (mths)61.9 (25.2)34.8 (24.6)
SEs reportedMinimal reporting-GI Symptoms, GB sludge, ?pancreatitisN/A
Other Rx1 patient had PRRT

Conclusion: These data indicate that mean duration of 4 years SSA treatment is associated with stable size or reduction (20%) in pNETs averaging 1.5 cm in patients with MEN1. Multi-centre collaboration, including comparison of a larger untreated cohort would clarify the effectiveness of SSA preventing progression on pNETs in MEN1.

Reference: Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.